Anti-ErbB targeted therapy and urothelial tumors;Thérapeutiques ciblées anti-ErbB et tumeurs urothéliales

Progres en Urologie

Volumn 15, Issue 6 SUPPL. 1, 2005, Pages 1229-1235

  Amsellem Ouazana, Delphine ^a   Goldwasser, François ^a   Bieche, Ivan ^b   Lidereau, Rosette ^b   Zerbib, Marc ^a  

^a Hôpital Cochin ^*  (France)

^b CENTRE RENÉ HUGUENIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER TUMOR; DRUG EFFECT; GENETICS; HUMAN; PHYSIOLOGY; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; GENES, ERBB; HUMANS; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 33749056619     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. ADAM R.M., DANCIU T., MCLELLAN D.L., BORER J.G., LIN J., ZURAKOWSKI D., WEINSTEIN M.H., RAJJAYABUN P.H., MELLON J.K.,FREEMAN M.R.: A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma. Cancer Res, 2003, 63, 484-490.
2. ALROY I.,YARDEN Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett, 1997, 410, 83-86.
3. AL-SUKHUN S.,HUSSAIN M.: Molecular biology of transitional cell carcinoma. Crit Rev Oncol Hematol, 2003, 47, 181-193.
4. AMSELLEM-OUAZANA D., BEUZEBOC P., PEYROMAURE M., VIELLEFOND A., ZERBIB M.,DEBRE B.: Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression. Ann Oncol, 2004, 15, 538.
5. AMSELLEM-OUAZANA D., BIECHE I., TOZLU S., BOTTO H., DEBRE B.,LIDEREAU R.: Gene expression profiling of ERBB receptors and ligands in human transitional carcinoma of the bladder. J Urol In Press, 2006,
6. BASELGA J.,AVERBUCH S.D.: ZD1839 ("Iressa") as an anticancer agent. Drugs, 2000, 60, 33-40.
7. BELLMUNT J., HUSSAIN M.,DINNEY C.P.: Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol, 2003, 46 Suppl, 85-104.
8. BIECHE I., ONODY P., TOZLU S., DRIOUCH K., VIDAUD M.,LIDEREAU R.: Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer, 2003, 106, 758-765.
9. CHOW N.H., CHAN S.H., TZAI T.S., HO C.L.,LIU H.S.: Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res, 2001, 7, 1957-1962.
10. CHOW N.H., LIU H.S., YANG H.B., CHAN S.H.,SU I.J.: Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study. Virchows Arch, 1997, 430, 461-466.
11. CHUNG K.Y., SHIA J., KEMENY N.E., SHAH M., SCHWARTZ G.K., TSE A., HAMILTON A., PAN D., SCHRAG D., SCHWARTZ L., KLIMSTRA D.S., FRIDMAN D., KELSEN D.P.,SALTZ L.B.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol, 2005, 23, 1803-1810.
12. CIARDIELLO F., CAPUTO R., BIANCO R., DAMIANO V., G. P., DE PLACIDO S., BIANCO A.C.,TORTORA G.: Anti-tumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res, 2000, 6, 2053-2063.
13. COOGAN C.L., ESTRADA C.R., KAPUR S.,BLOOM K.J.: HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology, 2004, 63, 786-790.
14. DE BONO J.S.,ROWINSKY E.K.: The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med, 2002, 8, S19-26.
15. DOMINGUEZ-ESCRIG J.L., KELLY J.D., NEAL D.E., KING S.M.,DAVIES B.R.: Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res, 2004, 10, 4874-4884.
16. ELLIS I.O., DOWSETT M., BARTLETT J., WALKER R., COOKE T., GULLICK W., GUSTERSON B., MALLON E.,LEE P.B.: Recommendations for HER2 testing in the UK. J Clin Pathol, 2000, 53, 890-892.
17. FRANKLIN W.A., VEVE R., HIRSCH F.R., HELFRICH B.A.,BUNN P.A., JR.: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol, 2002, 29, 3-14.
18. GANDOUR-EDWARDS R., LARA P.N., JR., FOLKINS A.K., LASALLE J.M., BECKETT L., LI Y., MEYERS F.J.,DEVERE-WHITE R.: Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer, 2002, 95, 1009-1015.
19. GULLICK W.J.,SRINIVASAN R.: The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat, 1998, 52, 43-53.
20. HACKEL P.O., ZWICK E., PRENZEL N.,ULLRICH A.: Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol, 1999, 11, 184-189.
21. HERMANEK P., WITTEKIND C.,SEIB H.J.: [Current TNM aspects. 5. TNM classification and stage grouping]. Zentralbl Chir, 1997, 122, 934-937.
22. HUSSAIN M., PETRYLAK D., DUNN R., VAISHAMPAYAN U., LARA P.N., JR.,CHATTA G.: Trastuzumab, paclitaxel, carboplatin and gemcitabine in advanced HER2-positive urothelial carcinoma: results of a multicentre phase II NCI trial. J Clin Oncol, 2005, 23, 379s.
23. JUNTTILA T.T., LAATO M., VAHLBERG T., SODERSTROM K.O., VISAKORPI T., ISOLA J.,ELENIUS K.: Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res, 2003, 9, 5346-5357.
24. KASSOUF W., DINNEY C.P., BROWN G., MCCONKEY D.J., DIEHL A.J., BAR-ELI M.,ADAM L.: Uncoupling between Epidermal Growth Factor Receptor and Downstream Signals Defines Resistance to the Antiproliferative Effect of Gefitinib in Bladder Cancer Cells. Cancer Res, 2005, 65, 10524-10535.
25. KROFT S.H.,OYASU R.: Urinary bladder cancer: mecanism of development and progression. Lab Invest, 1994, 71, 158-174.
26. KRUGER S., WEITSCH G., BUTTNER H., MATTHIENSEN A., BOHMER T., MARQUARDT T., SAYK F., FELLER A.C.,BOHLE A.: HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer, 2002, 102, 514-518.
27. LEBRET T., HERVÉ J.M., YONNEAU L., BARRÉ P., LUGAGNE P.M., BUTREAU M., MOLINIÉ V.,BOTTO H.: [Study of survival after cystectomy for bladder cancer. Report of 504 cases.]. Prog Urol, 2000, 10, 553-560.
28. LIPPONEN P.: Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer, 1993, 29A, 749-753.
29. LIPPONEN P.,ESKELINEN M.: Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer, 1994, 69, 1120-1125.
30. LYNCH T.J., BELL D.W., SORDELLA R., GURUBHAGAVATULA S., OKIMOTO R.A., BRANNIGAN B.W., HARRIS P.L., HASERLAT S.M., SUPKO J.G., HALUSKA F.G., LOUIS D.N., CHRISTIANI D.C., SETTLEMAN J.,HABER D.A.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350, 2129-2139.
31. MELLON J.K., LUNEC J., WRIGHT C., HORNE C.H., KELLY P.,NEAL D.E.: C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol, 1996, 155, 321-326.
32. MELLON K., WRIGHT C., KELLY P., HORNE C.H.,NEAL D.E.: Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol, 1995, 153, 919-925.
33. MENDELSOHN J.,BASELGA J.: The EGF receptor family as targets for cancer therapy. Oncogene, 2000, 19, 6550-6565.
34. MODLICH O., PRISACK H.B., PITSCHKE G., RAMP U., ACKERMANN R., BOJAR H., VOGELI T.A.,GRIMM M.O.: Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res, 2004, 10, 3410-3421.
35. MOSTOFI F.K., SOBIN L.H.,TORLONI H. International histological classification of tumours. Histological typing of urinary bladder tumours. 1973,
36. NEAL D.E., MARSH C., BENNETT M.K., ABEL P.D., HALL R.R., SAINSBURY J.R.,HARRIS A.L.: Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet, 1985, 1, 366-368.
37. NICOLE G., VORDOS D., DAHER A., MAILLE P., BAKKAR A., PAGES C., JOUAULT H., GIL DIEZ DE MEDINA S., CHOPIN D.,ABBOU C.C.: Gefitinib, un inhibiteur pharmacologique de EGFR inhibe la croissance et l'invasion de lignées cellulaires urothéliales porteuses d'une activation constitutionnelle de ErbB1. Prog Urol, 2005, 15, 16A.
38. OHTA J.I., MIYOSHI Y., UEMURA H., FUJINAMI K., MIKATA K., HOSAKA M., TOKITA Y.,KUBOTA Y: Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer. Clin Cancer Res, 2001, 7, 2463-2467.
39. OLAYIOYE M.A., NEVE R.M., LANE H.A.,HYNES N.E.: The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J, 2000, 19, 3159-3167.
40. ORNTOFT T.F.,WOLF H.: Molecular alterations in bladder cancer. Urol Res, 1998, 26, 223-233.
41. PENAULT-LLORCA F., BALATON A., SABOURIN J.-C., LE DOUSSAL V.,GEFPICS: Evaluation immunohistochimique du statut her2 dans les carcinomes mammaires infiltrants : mise au point du protocole technique et de la lecture des résultats - recommendations. ANN PATHOL, 2002, 22, 150-157.
42. PEYROMAURE M., SCOTTE F., AMSELLEM-OUAZANA D., VIEILLEFOND A., OUDARD S.,BEUZEBOC P.: Trastuzumab (Herceptintrade mark) in Metastatic Transitional Cell Carcinoma of the Urinary Tract: Report on Six Patients. Eur Urol, 2005, 48, 771-778.
43. PICH A., CHIUSA L., FORMICONI A., GALLIANO D., BORTOLIN P., COMINO A.,NAVONE R.: Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer, 2002, 95, 784-790.
44. RAJKUMAR T., STAMP G.W., PANDHA H.S., WAXMAN J.,GULLICK W.J.: Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB2 and c-erbB3 in bladder cancer. J Pathol, 1996, 179, 381-385.
45. RAVERY V., COLOMBEL M., POPOV Z., BASTUJI S., PATARD J.J., BELLOT J., ABBOU C.C., FRADET Y.,CHOPIN D.K.: Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. Br J Cancer, 1995, 71, 196-200.
46. RISCHMANN P.: Recommendations du Comité de Cancérologie de l'Association Française d'urologie. Tumeurs urothéliales. Prog Urol, 1998, 8, 25-50.
47. SALTZ L.B., MEROPOL N.J., LOEHRER P.J., SR., NEEDLE M.N., KOPIT J.,MAYER R.J.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 2004, 22, 1201-1208.
48. SATO K., MORIYAMA M., MORI S., SAITO M., WATANUKI T., TERADA K., OKUHARA E., AKIYAMA T., TOYOSHIMA K., YAMAMOTO T.,ET AL.: An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer, 1992, 70, 2493-2498.
49. SIROTNAK F.M., ZAKOWSKI M.F., MILLER V.A., SCHER H.I.,KRIS M.G.: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res, 2000, 6, 4885-4892.
50. SLAMON D.J., CLARK G.M., WONG S.G., LEVIN W.J., ULLRICH A.,MC GUIRE W.L.: Human breast cancer correlation of relapse and survival with amplification of the her-2/neu oncogene. SCIENCE, 1987, 235, 177-182.
51. SLAMON D.J., LEYLAND-JONES B., SHAK S., FUCHS H., PATON V., BAJAMONDE A., FLEMING T., EIERMANN W., WOLTER J., PEGRAM M., BASELGA J., NORTON L.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001, 344, 783-792.
52. SRIPLAKICH S., JAHNSON S.,KARLSSON M.G.: Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer? BJU Int, 1999, 83, 498-503.
53. STRACHAN L., MURISON J.G., PRESTIDGE R.L., SLEEMAN M.A., WATSON J.D.,KUMBLE K.D.: Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J Biol Chem, 2001, 276, 18265-18271.
54. THOGERSEN V.B., SORENSEN B.S., POULSEN S.S., ORNTOFT T.F., WOLF H.,NEXO E.: A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res, 2001, 61, 6227-6233.
55. UNDERWOOD M., BARTLETT J., REEVES J., GARDINER D.S., SCOTT R.,COOKE T.: C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res, 1995, 55, 2422-2430.
56. VOLLMER R.T., HUMPHREY P.A., SWANSON P.E., WICK M.R.,HUDSON M.L.: Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer, 1998, 82, 715-723.
57. WOOD D.P., JR., WARTINGER D.D., REUTER V., CORDON-CARDO C., FAIR W.R.,CHAGANTI R.S.: DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder. J Urol, 1991, 146, 1398-1401.
58. WRIGHT C., MELLON K., JOHNSTON P., LANE D.P., HARRIS A.L., HORNE C.H.,NEAL D.E.: Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer, 1991, 63, 967-970.
59. YARDEN Y.,SLIWKOWSKI M.X.: Untangling the ErbB signalling network. Nature Reviews. Molecular cell biology., 2001, 2, 127-137.
60. ZERBIB M.,BOUCHOT O.: [Results of cystectomy for cancer.]. Prog Urol, 2002, 12, 913-922.